Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: A randomized controlled trial

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 418-423

  Naritoku, Dean K ^a   Hulihan, Joseph F ^b   Schwarzman, Lesley Kraut ^b   Kamin, Marc ^c   Olson, William H ^d  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ortho McNeil Pharmaceutical   (United States)

^c Ortho McNeil Pharmaceutical   (United States)

^d Ortho McNeil Pharmaceutical   (United States)

Author keywords

Antiepileptic drug; Epilepsy; Seizures; Tolerability; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ANOREXIA; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; CAUSE OF DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TREATMENT FAILURE; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED;

EID: 13944278744     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E403     Document Type: Article

References (14)

1. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-16.
2. Messenheimer JA. Lamotrigine. Epilepsia 1995;36(suppl 2):S87-94.
3. Bares G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-607.
4. Reife R, Pledger G, Wu S-C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(suppl 1):S66-71.
5. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M. Topiramate titration and tolerability. Ann Pharmacother 2001; 35:173-9. DOI 10.1345/aph.10093
6. Guberman A, Neto W, Gassmann-Mayer C, the EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002;106:183-9.
7. Package insert. Topamax (topiramate). Raritan, NJ: Ortho-McNeil Pharmaceutical, July 1999.
8. From the Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22:489-501.
9. Deckers CLP, Hekster YA, Keyser A, van Lier HJJ, Meinardi H, Renier WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001;42:1387-94.
10. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-96.
11. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993;46:409-27.
12. Chadwick DW, Annul H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial epilepsies. Neurology 1998;51:1282-8.
13. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
14. Dodson WE, Kamin M, Kraut L, Olson WH, Wu S-C. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother, 2003;37:615-20. DOI 10.1345/aph.1C133